Viatris revenue
Viatris's revenue was $14.30bn in fiscal 2025, down 3.0% on the year before. Since fiscal 2018 ($11.43bn) it has grown at a compound 3.2% a year. Over the last twelve months it was $14.74bn.
Revenue history
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.4 | 11.5 | 11.9 | 17.9 | 16.3 | 15.4 | 14.7 | 14.3 | 14.7 |
| Growth on the year before | — | +0.6% | +3.9% | +49.7% | −9.1% | −5.1% | −4.5% | −3.0% | — |
| Gross profit | 4.0 | 3.9 | 3.8 | 5.6 | 6.5 | 6.4 | 5.6 | 5.0 | 5.1 |
| Gross margin | 35.0% | 33.9% | 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% | 34.8% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Brands | $9.2B | ▼ 0.2% |
| Generics | $5.1B | ▼ 7.8% |
| Lipitor | $1.5B | ▲ 5.5% |
| Norvasc | $710M | ▲ 5.4% |
| Lyrica | $487M | ▼ 1.7% |
| Epi Pen Auto Injectors | $470M | ▲ 19.8% |
| Viagra | $408M | ▲ 3.2% |
| Creon | $366M | ▲ 11.5% |
| Celebrex | $273M | ▼ 4.4% |
| Yupelri | $267M | ▲ 11.9% |
| Effexor | $258M | ▲ 1.9% |
| Zoloft | $255M | ▲ 8.1% |
| Influvac | $194M | ▲ 8.8% |
| Dymista | $164M | ▼ 13.0% |
| Xalabrands | $158M | ▼ 4.8% |
| Amitiza | $158M | ▲ 6.0% |
| Xanax | $140M | ▼ 3.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | YoY |
|---|---|---|
| United States | $3B | ▼ 12.5% |
| China | $2.1B | ▲ 8.8% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Viatris's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Viatris | $14.74bn | 4.4% | -1.9% |
| Haleon plc | $14.55bn | 1.3% | — |
| Universe Pharmaceuticals Inc | $17.86bn | -22.4% | — |
| Bausch Health Companies Inc. | $11.11bn | 10.8% | 9.2% |
| Zoetis | $9.52bn | 1.5% | 5.0% |
| Organon & Co. | $6.10bn | -3.2% | -0.3% |
Compare with peers
- Haleon plc revenue
- Universe Pharmaceuticals Inc revenue
- Bausch Health Companies Inc. revenue
- Zoetis revenue
- Organon & Co. revenue
Head to head: HLN vs VTRSUPC vs VTRSBHC vs VTRSVTRS vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies